

Colin P Dinney

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6687651/colin-p-dinney-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

342
papers

17,941
citations

73
h-index

118
g-index

368
ext. papers

20,907
ext. citations

4.9
avg, IF

6.21
L-index

#	Paper	IF	Citations
342	Reduced Dose Intravesical Bacillus Calmette-Guëin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022 , 1-5	1	0
341	Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.. <i>BJU Compass</i> , 2022 , 3, 37-44	0.9	0
340	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022 , 207, 70-76	2.5	1
339	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guëin. <i>BJU International</i> , 2021 , 128, 65-71	5.6	3
338	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002266	2.5	0
337	Time interval from transurethral resection of bladder tumour to bacille Calmette-Guëin induction does not impact therapeutic response. <i>BJU International</i> , 2021 , 128, 634-641	5.6	1
336	Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. <i>Bladder Cancer</i> , 2021 , 7, 243-252	1	2
335	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 301.e17-301.e28	2.8	1
334	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 1620-1621	2.5	0
333	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guëin: Implications for Clinical Trial Design. <i>Journal of Urology</i> , 2021 , 205, 1612-1621	2.5	5
332	Progression of Disease after Bacillus Calmette-Guëin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021 , 206, 1258-1267	2.5	2
331	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. <i>World Journal of Urology</i> , 2021 , 39, 4143-4149	4	2
330	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2021 , 79, 428-429	10.2	1
329	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021 , 127, 528-537	5.6	1
328	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 237.e1-237.e5	2.8	0
327	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology, The</i> , 2021 , 22, 107-117	21.7	53
326	Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021 , 128, 568-574	5.6	1

325	Oncologic Equipose Between Robotic and Open Radical Cystectomy. <i>Journal of Endourology</i> , 2021 , 35, 1168-1176	2.7	
324	Reply by Authors. <i>Journal of Urology</i> , 2021 , 206, 1267	2.5	
323	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021 , 39, 4345-4354	4	2
322	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. <i>Journal of Urology</i> , 2021 , 206, 548-557	2.5	4
321	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2021 , 206, 577-585	2.5	0
320	Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 22, 360-376	6.4	4
319	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. <i>Scientific Reports</i> , 2020 , 10, 9743	4.9	24
318	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 811-821	6.6	2
317	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 639.e1-639.e9	2.8	7
316	Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 247-254	2.8	2
315	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guñin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020 , 203, 283-291	2.5	3
314	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 3.e17-3.e27	2.8	15
313	Intravesical Gene Therapy. <i>Urologic Clinics of North America</i> , 2020 , 47, 93-101	2.9	4
312	Bacillus Calmette-Guñin Salvage Therapy: Definitions and Context. <i>Urologic Clinics of North America</i> , 2020 , 47, 1-4	2.9	2
311	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 882-891	12.9	39
310	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020 , 26, 1845-1851	50.5	72
309	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>iScience</i> , 2020 , 23, 101206.1		7
308	Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. <i>Journal of Sexual Medicine</i> , 2020 , 17, 1995-2004	1.1	1

307	Overall survival in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2020 , 10, 25-35	2.2	12
306	Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. <i>European Urology Focus</i> , 2020 , 6, 88-94	5.1	17
305	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 420-433	10.2	309
304	Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2020 , 154, 208-214	1.9	2
303	Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. <i>Onc Immunology</i> , 2019 , 8, e1577125	7.2	6
302	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. <i>Cell Reports</i> , 2019 , 27, 1781-1793.e4	10.6	53
301	Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2019 , 75, 1034-1035	10.2	1
300	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019 , 37, 2691-2698	4	5
299	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 354.e19-354.e26	2.8	3
298	Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 13, 24-28	1.2	19
297	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 51-60	4	25
296	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1790-1798	13.4	5
295	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. <i>Cell Reports</i> , 2019 , 26, 2241-2256.e4	10.6	15
294	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. <i>European Urology Oncology</i> , 2019 , 2, 286-293	6.7	5
293	The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. <i>World Journal of Urology</i> , 2019 , 37, 2041-2049	4	8
292	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. <i>European Urology</i> , 2019 , 75, 8-10	10.2	20
291	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. <i>European Urology Focus</i> , 2019 , 5, 664-675	5.1	4
290	Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. <i>American Journal of Clinical Nutrition</i> , 2018 , 107, 208-216	7	12

289	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. <i>BJU International</i> , 2018 , 122, 89-98	5.6	9
288	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. <i>Molecular Pathology Library</i> , 2018 , 85-101		
287	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. <i>Supportive Care in Cancer</i> , 2018 , 26, 1561-1568	3.9	8
286	Cancer risk associated with chronic diseases and disease markers: prospective cohort study. <i>BMJ, The</i> , 2018 , 360, k134	5.9	57
285	Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Surgical Innovation</i> , 2018 , 25, 242-250	2	19
284	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2018 , 4, 720-724	5.1	14
283	Risk factors for falls in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2018 , 8, 34-37	2.2	18
282	Effects of thiazolidinedione in patients with active bladder cancer. <i>BJU International</i> , 2018 , 121, 244-251	5.6	3
281	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 81-83	3.6	8
280	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 71	7.7	30
279	Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. <i>Journal of Endourology</i> , 2018 , 32, 806-811	2.7	1
278	Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2018 , 9, 14895-14908	3.3	14
277	Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2018 , 142, 1797-1804	7.5	10
276	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. <i>Human Pathology</i> , 2018 , 79, 57-65	3.7	27
275	Salvage topical therapy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 2027-2034	3.4	6
274	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2017 , 3, 258-264	5.1	38
273	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , 2017 , 161, 1246-1254	3.6	14
272	Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. <i>Drugs in R and D</i> , 2017 , 17, 297-304	3.4	10

271	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017 , 35, 1729-1736	4	7
270	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 500-506	1.9	36
269	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. <i>Scientific Reports</i> , 2017 , 7, 40714	4.9	31
268	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. <i>Oncotarget</i> , 2017 , 8, 12657-12667	7.2	13
267	Intravesical rAd-IFN γ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3410-3416	2.2	86
266	High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. <i>Human Pathology</i> , 2017 , 67, 1263-1268	3.3	1
265	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. <i>Journal of Endourology</i> , 2017 , 31, 946-953	2.7	22
264	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017 , 3, 577-583	5.1	10
263	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU International</i> , 2017 , 119, 684-691	5.6	24
262	Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. <i>Asian Journal of Urology</i> , 2017 , 4, 124-127	2.7	1
261	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2017 , 3, 147-148	1	1
260	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 145-146	1	5
259	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. <i>Oncotarget</i> , 2017 , 8, 34205-34222	3.3	12
258	Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. <i>Oncotarget</i> , 2017 , 8, 88782-88791	2.3	3
257	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 59.e1-8	2.8	33
256	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 695-701	4	1
255	Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. <i>European Urology</i> , 2016 , 69, 197-200	10.2	91
254	Summary and Recommendations from the National Cancer Institute Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202	1	22

253	Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. <i>Medicine (United States)</i> , 2016 , 95, e4500	1.8	1
252	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 469-76	2.8	7
251	Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. <i>BJU International</i> , 2016 , 117, 754-60	5.6	26
250	Origins of Bladder Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016 , 11, 149-74	34	101
249	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016 , 25, 1203-14	5.6	20
248	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016 , 69, 955-62	10.2	163
247	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. <i>Genes and Cancer</i> , 2016 , 7, 229-239	2.9	11
246	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016 , 7, 80164-80174	3.3	28
245	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon β Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 4110-4114	3.1	13
244	Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. <i>European Urology</i> , 2016 , 70, 778-785	10.2	17
243	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016 , 70, 611-620	10.2	92
242	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016 , 3, 260-267	2.7	18
241	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. <i>EBioMedicine</i> , 2016 , 12, 105-117	8.8	169
240	Genetic Variants in the Wnt/ β Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. <i>Journal of Urology</i> , 2015 , 194, 1771-6	2.5	30
239	Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. <i>Cancer Prevention Research</i> , 2015 , 8, 607-13	3.2	15
238	Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4104-10	3.1	24
237	Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 377-94, x-xi	3.1	45
236	Urachal carcinoma: a pathologic and clinical study of 46 cases. <i>Human Pathology</i> , 2015 , 46, 1808-14	3.7	54

235	Genetic subtypes of invasive bladder cancer. <i>Current Opinion in Urology</i> , 2015 , 25, 449-58	2.8	28
234	Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 4097-109	3.3	1
233	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. <i>Bladder Cancer</i> , 2015 , 1, 29-30	1	59
232	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2015 , 67, 241-9	10.2	178
231	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjö Dahl, and Mattias Håglund Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. <i>Eur Urol</i> 2014;66:609-10. <i>European Urology</i> , 2015 , 67, e76-8	10.2	3
230	Clinical outcomes of cT1 micropapillary bladder cancer. <i>Journal of Urology</i> , 2015 , 193, 1129-34	2.5	69
229	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2015 , 4, 273-82	2.3	4
228	Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. <i>Urology</i> , 2014 , 83, 262-4	1.6	48
227	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98	5.6	101
226	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. <i>Cancer Cell</i> , 2014 , 25, 152-65	24.3	977
225	Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. <i>Urology</i> , 2014 , 84, 1147-51	1.6	15
224	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014 , 11, 400-10	5.5	189
223	Reply by the authors. <i>Urology</i> , 2014 , 84, 495-6	1.6	2
222	Micropapillary bladder cancer: current treatment patterns and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 826-32	2.8	39
221	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 1794-9	6.4	132
220	Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 287-95		36
219	Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. <i>Journal of Urology</i> , 2014 , 191, 40-7	2.5	122
218	Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 864-71	1.9	33

217	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
216	Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1108-15	2.8	23
215	Clinical significance of ureteric skip lesions at the time of radical cystectomy: the M.D. Anderson experience and literature review. <i>BJU International</i> , 2014 , 113, E28-33	5.6	14
214	Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. <i>Urology</i> , 2014 , 83, 863-7	1.6	69
213	Differential expression of GATA-3 in urothelial carcinoma variants. <i>Human Pathology</i> , 2014 , 45, 1466-72	3.7	40
212	Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. <i>British Journal of Cancer</i> , 2013 , 108, 2372-80	8.7	22
211	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 480-6	2.8	25
210	ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. <i>European Urology</i> , 2013 , 63, 36-44	10.2	117
209	Plasma microRNA profiles for bladder cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1701-8	2.8	71
208	Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. <i>Journal of Urology</i> , 2013 , 189, 1656-61	2.5	107
207	Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. <i>Journal of Urology</i> , 2013 , 190, 1404-9	2.5	24
206	Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013 , 64, 307-13	10.2	106
205	Phase I trial of intravesical recombinant adenovirus mediated interferon- β formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2013 , 190, 850-6	2.5	76
204	Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1635-42	2.8	92
203	Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. <i>Carcinogenesis</i> , 2013 , 34, 1006-11	4.6	22
202	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. <i>Cancer</i> , 2013 , 119, 540-7	6.4	63
201	The p63 protein isoform Δ p63 inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. <i>Journal of Biological Chemistry</i> , 2013 , 288, 3275-88	5.4	95
200	Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. <i>BJU International</i> , 2013 , 111, 1068-74	5.6	51

199	Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1245-54	6.1	65
198	Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013 , 39, 817-22	2	3
197	Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. <i>PLoS ONE</i> , 2013 , 8, e57284	3.7	55
196	Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. <i>PLoS ONE</i> , 2013 , 8, e69509	3.7	30
195	Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. <i>BJU International</i> , 2012 , 110, E590-5	5.6	19
194	Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. <i>Cancer</i> , 2012 , 118, 205-15	6.4	12
193	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2012 , 30, 753-9	4	23
192	Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. <i>Journal of Urology</i> , 2012 , 187, 862-7	2.5	55
191	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 821-4	2.8	23
190	Upper tract urothelial carcinoma: impact of time to surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 266-72	2.8	33
189	Uncommon Cancers of the Bladder 2012 , 23-33		2
188	Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. <i>PLoS ONE</i> , 2012 , 7, e38533	3.7	23
187	Detection of bladder cancer using proteomic profiling of urine sediments. <i>PLoS ONE</i> , 2012 , 7, e42452	3.7	8
186	Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. <i>International Journal of Cancer</i> , 2012 , 131, 1892-903	7.5	19
185	Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1325-38	4.6	23
184	p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 477-86	4.6	14
183	p63 expression defines a lethal subset of muscle-invasive bladder cancers. <i>PLoS ONE</i> , 2012 , 7, e30206	3.7	58
182	Genetic variants in telomere-maintenance genes and bladder cancer risk. <i>PLoS ONE</i> , 2012 , 7, e30665	3.7	15

181	Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. <i>PLoS ONE</i> , 2012 , 7, e51758	3.7	18
180	Boosted C5 Trees i-Biomarkers Panel for Invasive Bladder Cancer Progression Prediction. <i>Lecture Notes in Computer Science</i> , 2012 , 190-200	0.9	
179	Small Cell Urothelial Carcinoma 2012 , 173-181		
178	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 456-61	2.5	70
177	Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. <i>Journal of Urology</i> , 2011 , 185, 79-83	2.5	48
176	Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 693-700	2.5	22
175	Intelligent Clinical Decision Support Systems for Non-invasive Bladder Cancer Diagnosis. <i>Lecture Notes in Computer Science</i> , 2011 , 253-262	0.9	2
174	Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. <i>Urology</i> , 2011 , 78, 61-7	1.6	37
173	The role of radical cystectomy in patients with clinical T4b bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 157-61	2.8	12
172	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. <i>BJU International</i> , 2011 , 107, 898-904	5.6	136
171	Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. <i>BJU International</i> , 2011 , 108, 1119-23	5.6	51
170	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011 , 108, 687-92	5.6	19
169	Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. <i>Journal of Urology</i> , 2011 , 185, 1216-21	2.5	27
168	A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 514-21	3.2	60
167	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. <i>Urologia Internationalis</i> , 2011 , 87, 42-8	1.9	17
166	New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. <i>Clinical Cancer Research</i> , 2011 , 17, 2608-12	12.9	79
165	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. <i>Human Molecular Genetics</i> , 2011 , 20, 4282-9	5.6	82
164	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 978-84	36.3	408

163	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010 , 105, 1402-12	5.6	114
162	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. <i>BJU International</i> , 2010 , 106, 1799-804	5.6	31
161	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. <i>Carcinogenesis</i> , 2010 , 31, 1387-91	4.6	52
160	The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , 2010 , 16, 4461-7	12.9	107
159	Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 1235-45	3.2	42
158	Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 505-17	3.2	27
157	Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. <i>American Journal of Roentgenology</i> , 2010 , 195, 959-65	5.4	42
156	Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. <i>Journal of Urology</i> , 2010 , 183, 87-93	2.5	50
155	Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. <i>Journal of Urology</i> , 2010 , 184, 888-94	2.5	52
154	Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. <i>Journal of Urology</i> , 2010 , 183, 2165-70	2.5	159
153	Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. <i>Urology</i> , 2010 , 76, 1419-24	1.6	76
152	The International Bladder Cancer Network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 375-6	2.8	2
151	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 429-40	2.8	160
150	Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. <i>Journal of Urology</i> , 2010 , 183, 929-34	2.5	77
149	Management of urethral recurrence after orthotopic urinary diversion. <i>BJU International</i> , 2010 , 106, 56-61	5.6	19
148	Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. <i>European Urology</i> , 2010 , 57, 300-9	10.2	127
147	Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. <i>Cancer</i> , 2010 , 116, 340-6	6.4	43
146	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. <i>Cancer</i> , 2010 , 116, 3127-34	6.4	174

145	A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. <i>Cancer</i> , 2010 , 116, 4513-9	6.4	28
144	Self-assembled fluorescent magnetic nanoprobe for multimode-biomedical imaging. <i>Biomaterials</i> , 2010 , 31, 9310-9	15.6	50
143	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. <i>Carcinogenesis</i> , 2009 , 30, 2047-52	4.6	70
142	Novel therapeutics for patients with non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 807-13	3.5	5
141	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
140	Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2090-7	4	38
139	The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. <i>Cancer Prevention Research</i> , 2009 , 2, 1001-2	3.2	2
138	Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2592-7	2.2	120
137	Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. <i>European Urology</i> , 2009 , 56, 745-6	10.2	1
136	Urological cancers. Preface. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 267	9.6	
135	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 335-44	9.6	272
134	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2009 , 41, 991-5	36.3	270
133	miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5060-72	12.9	353
132	Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. <i>Urology</i> , 2009 , 73, 147-52	1.6	53
131	Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures. <i>Urology</i> , 2009 , 73, 1175-8	1.6	6
130	Cardiac history and risk of post-cystectomy cardiac complications. <i>Urology</i> , 2009 , 74, 1085-9	1.6	12
129	The impact of variant histology on the outcome of bladder cancer treated with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 3-7	2.8	176
128	Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. <i>Human Pathology</i> , 2009 , 40, 1448-52	3.7	41

127	The stabilization and targeting of surfactant-synthesized gold nanorods. <i>Nanotechnology</i> , 2009 , 20, 4340-5	9.4	82
126	EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY. <i>Journal of Urology</i> , 2009 , 181, 629	2.5	12
125	High risk populations and cystectomy outcomes. <i>Journal of Urology</i> , 2009 , 182, 10-1	2.5	2
124	Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. <i>Laboratory Investigation</i> , 2008 , 88, 694-721	5.9	55
123	Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. <i>DNA Repair</i> , 2008 , 7, 141-8	4.3	64
122	Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. <i>Journal of Urology</i> , 2008 , 179, 353-8	2.5	66
121	Clinical model of cost of bladder cancer in the elderly. <i>Urology</i> , 2008 , 71, 519-25	1.6	37
120	Bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 479-80	2.8	
119	Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?. <i>Journal of Urology</i> , 2008 , 180, 1146-53	2.5	4
118	Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. <i>Journal of Urology</i> , 2008 , 180, 164-7; discussion 167	2.5	34
117	Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. <i>Clinical Cancer Research</i> , 2008 , 14, 2236-44	12.9	44
116	Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1401-11	9.7	63
115	Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. <i>Clinical Cancer Research</i> , 2008 , 14, 1478-86	12.9	85
114	Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. <i>Journal of Clinical Oncology</i> , 2008 , 26, 121-6	2.2	148
113	Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. <i>Cancer Research</i> , 2008 , 68, 2530-7	10.1	215
112	Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2445-50	4	12
111	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 224-9	12.9	54
110	Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. <i>Cancer Causes and Control</i> , 2008 , 19, 981-92	2.8	26

109	Growth factors and receptors as prognostic markers in urothelial carcinoma. <i>Current Urology Reports</i> , 2008 , 9, 55-61	2.9	39
108	Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. <i>Cancer</i> , 2008 , 112, 2467-74	6.4	45
107	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1015-26	3.5	10
106	Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 1900-6	2.5	16
105	Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2007 , 178, 2302-6; discussion 2307	2.5	112
104	Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. <i>International Journal of Cancer</i> , 2007 , 120, 2208-13	7.5	62
103	Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. <i>Cancer</i> , 2007 , 110, 62-7	6.4	220
102	Risk assessment of renal cell carcinoma using alkaline comet assay. <i>Cancer</i> , 2007 , 110, 282-8	6.4	13
101	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. <i>Cancer</i> , 2007 , 110, 764-9	6.4	70
100	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. <i>BJU International</i> , 2007 , 100, 1377-84	5.6	57
99	P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. <i>European Urology</i> , 2007 , 52, 769-74	10.2	52
98	Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 623-34	9.6	95
97	Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. <i>Carcinogenesis</i> , 2007 , 28, 698-703	4.3	36
96	Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. <i>Clinical Cancer Research</i> , 2007 , 13, 2614-20	12.9	52
95	Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2007 , 6, 872-9	4.6	44
94	Emerging drugs for targeted therapy of bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 435-48	3.7	5
93	High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. <i>Carcinogenesis</i> , 2007 , 28, 2160-5	4.6	61
92	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 277-85	6.1	56

91	Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. <i>Cancer Research</i> , 2007 , 67, 1430-5	10.1	73
90	Projecting individualized probabilities of developing bladder cancer in white individuals. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4974-81	2.2	63
89	High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 84-91†		81
88	Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. <i>Urology</i> , 2007 , 70, 252-6	1.6	90
87	Organ preservation for muscle-invasive bladder cancer by transurethral resection. <i>Urology</i> , 2007 , 70, 473-6	1.6	35
86	Review of the M.D. Anderson experience in the treatment of bladder sarcoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 38-45	2.8	52
85	Targeted therapies in bladder cancer--an update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 433-8	2.8	70
84	Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. <i>Journal of Urology</i> , 2007 , 178, 1492-6	2.5	66
83	Genetic polymorphism in bladder cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 192-213	2.8	24
82	1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. <i>Journal of Urology</i> , 2007 , 177, 502-502	2.5	4
81	Bladder cancer risk as modified by family history and smoking. <i>Cancer</i> , 2006 , 107, 705-11	6.4	29
80	Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. <i>Cancer</i> , 2006 , 107, 1491-5	6.4	16
79	A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. <i>Nature Reviews Urology</i> , 2006 , 3, 472-3		1
78	Matrix metalloproteinase polymorphisms and bladder cancer risk. <i>Cancer Research</i> , 2006 , 66, 11644-8	10.1	61
77	Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1746-9	4	32
76	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. <i>Clinical Cancer Research</i> , 2006 , 12, 4671-7	12.9	56
75	Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3032-41	6.1	28
74	Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5528-35	2.2	62

73	Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. <i>Journal of Urology</i> , 2006 , 176, 1642-5	30
72	Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. <i>American Journal of Human Genetics</i> , 2006 , 78, 464-79	11 234
71	Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. <i>Journal of Urology</i> , 2006 , 175, 2058-62	2.5 109
70	The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. <i>Journal of Urology</i> , 2006 , 175, 881-5	2.5 165
69	Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. <i>Journal of Urology</i> , 2006 , 176, 53-7; discussion 57	2.5 80
68	Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. <i>Journal of Urology</i> , 2006 , 176, 1463-7	2.5 85
67	Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. <i>Journal of Urology</i> , 2006 , 176, 787-92	2.5 29
66	Upper urinary tract tumors with nontransitional histology: a single-center experience. <i>Urology</i> , 2006 , 67, 518-23	1.6 65
65	Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. <i>Urology</i> , 2006 , 67, 466-71	1.6 16
64	The use of urine-based biomarkers in bladder cancer. <i>Urology</i> , 2006 , 67, 62-4	1.6 8
63	Therapy of invasive bladder cancer. <i>Urology</i> , 2006 , 67, 56-9; discussion 60-1	1.6 30
62	Clinical model of lifetime cost of treating bladder cancer and associated complications. <i>Urology</i> , 2006 , 68, 549-53	1.6 209
61	Uncommon Cancers of the Bladder 2006 , 18-26	2
60	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. <i>Current Opinion in Urology</i> , 2006 , 16, 344-9	2.8 22
59	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. <i>BJU International</i> , 2006 , 98, 1176-80	5.6 104
58	Neoadjuvant chemotherapy for bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 531-42	4 24
57	1240: Prospective Evidence Supporting the Utility of Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center. <i>Journal of Urology</i> , 2006 , 175, 399-399	2.5 2
56	Clinical applications for targeted therapy in bladder cancer. <i>Urologic Clinics of North America</i> , 2005 , 32, 239-46, vii	2.9 6

55	The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. <i>Pharmacogenomics</i> , 2005 , 6, 575-84	2.6	14
54	The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. <i>Neoplasia</i> , 2005 , 7, 912-20	6.4	27
53	Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. <i>Laboratory Investigation</i> , 2005 , 85, 532-49	5.9	42
52	Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. <i>Cancer</i> , 2005 , 104, 975-84	6.4	117
51	Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 1408-15	12.9	83
50	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. <i>Cancer Research</i> , 2005 , 65, 10524-35	10.1	71
49	Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. <i>Cancer Research</i> , 2005 , 65, 4902-8	10.1	101
48	Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5746-56	2.2	123
47	Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. <i>Clinical Cancer Research</i> , 2005 , 11, 413-5	12.9	8
46	Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. <i>Cancer Research</i> , 2004 , 64, 4601-10	10.1	44
45	Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. <i>Cancer Research</i> , 2004 , 64, 8973-9	10.1	64
44	Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. <i>Molecular Therapy</i> , 2004 , 10, 525-32	11.7	56
43	Focus on bladder cancer. <i>Cancer Cell</i> , 2004 , 6, 111-6	24.3	221
42	Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. <i>Journal of Urology</i> , 2004 , 172, 481-4	2.5	180
41	Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. <i>Journal of Urology</i> , 2004 , 171, 570-4	2.5	67
40	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). <i>Current Opinion in Urology</i> , 2004 , 14, 295-300	2.8	16
39	The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 279-90	6.1	62
38	Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. <i>Journal of Urology</i> , 2003 , 169, 2113-7	2.5	75

37	Surveillance and management of recurrence for upper tract transitional cell carcinoma. <i>Urologic Clinics of North America</i> , 2003 , 30, 791-802	2.9	23
36	Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. <i>Urology</i> , 2003 , 61, 1151-5	1.6	50
35	Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 327-33	2.8	74
34	Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 456-62	2.8	31
33	If cystectomy is insufficient, what is an urologist to do?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 475-8	2.8	6
32	Genetic instability in bladder cancer assessed by the comet assay. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 540-7	9.7	76
31	Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2247-53	2.2	120
30	Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. <i>Cancer Research</i> , 2003 , 63, 4017-20	10.1	16
29	Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. <i>Clinical Cancer Research</i> , 2003 , 9, 3167-75	12.9	101
28	Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. <i>Cancer Gene Therapy</i> , 2002 , 9, 687-91	5.4	49
27	Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. <i>Clinical Cancer Research</i> , 2002 , 8, 1258-70	12.9	62
26	The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. <i>Clinical Cancer Research</i> , 2002 , 8, 1863-70	12.9	55
25	Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4005-13	2.2	250
24	Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. <i>American Journal of Pathology</i> , 2001 , 158, 735-43	5.8	151
23	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. <i>Journal of Urology</i> , 2001 , 165, 1152-1157	2.5	15
22	Gene therapy for superficial bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 531-9	3.5	5
21	Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. <i>Oncology Reports</i> , 2001 , 8, 955-64	3.5	22
20	Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. <i>Cancer</i> , 1999 , 86, 2212-6	6.4	41

19	Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. <i>Diagnostic Cytopathology</i> , 1999 , 20, 285-90	1.4	40
18	INTERLEUKIN-8 (IL-8) EXPRESSION REGULATES TUMORIGENICITY AND METASTASIS IN HUMAN BLADDER CANCER. <i>Journal of Urology</i> , 1999 , 120	2.5	14
17	STAGE SPECIFIC GUIDELINES FOR SURVEILLANCE AFTER RADICAL NEPHRECTOMY FOR LOCAL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1998 , 159, 1163-1167	2.5	286
16	Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , 1998 , 159, 394-8	2.5	130
15	RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 1998 , 160, 1285-1290	2.5	46
14	The Efficacy and Complications of Salvage Cryotherapy of the Prostate. <i>Journal of Urology</i> , 1997 , 157, 921-925	2.5	188
13	Risk of Urethral, Vaginal and Cervical Involvement in Patients Undergoing Radical Cystectomy for Bladder Cancer: Results of a Contemporary Cystectomy Series from M. D. Anderson Cancer Center. <i>Journal of Urology</i> , 1997 , 157, 2120-2123	2.5	64
12	Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. <i>Urology</i> , 1997 , 50, 673-7	1.6	42
11	Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. <i>Annals of Thoracic Surgery</i> , 1997 , 63, 1592-600	2.7	206
10	Radical cystectomy: posterior dissection following prior therapy. <i>Journal of Surgical Oncology</i> , 1997 , 64, 165-6	2.8	
9	The Risk of Upper Tract Recurrence Following Cystectomy in Patients with Transitional Cell Carcinoma Involving the Distal Ureter. <i>Journal of Urology</i> , 1996 , 155, 501-503	2.5	83
8	Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. <i>Urology</i> , 1996 , 47, 826-30	1.6	28
7	Isolation and Characterization of Metastatic Variants from Human Transitional Cell Carcinoma Passaged by Orthotopic Implantation in Athymic Nude Mice. <i>Journal of Urology</i> , 1995 , 154, 1532-1538	2.5	129
6	The Relationship of Local Control to Distant Metastasis in Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 1995 , 154, 2059-2064	2.5	75
5	Original Articles: Bladder Cancer: Management of Transitional Cell Carcinoma Involving Von Brunn® Nests. <i>Journal of Urology</i> , 1995 , 153, 944-949	2.5	6
4	Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. <i>Journal of Clinical Ultrasound</i> , 1995 , 23, 263-5	1	7
3	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> ,	1	8
2	The consensus molecular classification of muscle-invasive bladder cancer		6

- 1 Multi-targeted agents in the treatment of urothelial carcinoma 353-361